Income statement
USD
Annual
| Metric | 2024 | 2023 | 2022 | 2021 | 2019 |
|---|---|---|---|---|---|
| Revenue | 59K | 0 | 35K | 0 | 0 |
| Gross Profit | 31K | 0 | 35K | 0 | 0 |
| Operating Income | -1M | -270K | -181K | -36K | -2K |
| EBITDA | -1M | -147K | -181K | -133K | 271K |
| Net Income | -1M | -417K | -181K | -168K | 99K |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.0939
+0.00% today
1Y Change
-78.95%
Window
Jun 23, 2025 → Jun 8, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 8, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Polomar Health Services, Inc. (PMHS) is a Healthcare stock with listed on OTC. The stock last traded around $0.09 and down 78.9% across the available one-year price window (Jun 23, 2025 → Jun 8, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -1215.8%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -1215.8%, free cash flow -198.7% with operating margin -3927.5% and ROIC -32.8%. Valuation already assumes a fairly strong business story at price/sales 51.7. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines PMHS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PMHS
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PMHS Max Drawdown
-91.82%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PMHS and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
$99.1K
+158.8% YoY
Free Cash Flow
-$1.8K
+94.5% YoY
Revenue Growth
+0.0%
EPS Growth
-1215.8%
Gross Margin
51.2%
Net Margin
-3731.4%
Income statement
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2019 |
|---|---|---|---|---|---|
| Revenue | 59K | 0 | 35K | 0 | 0 |
| Gross Profit | 31K | 0 | 35K | 0 | 0 |
| Operating Income | -1M | -270K | -181K | -36K | -2K |
| EBITDA | -1M | -147K | -181K | -133K | 271K |
| Net Income | -1M | -417K | -181K | -168K | 99K |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 6K | 244 | 226K | 0 | 0 |
| Total Assets | 10M | 244 | 261K | 0 | 0 |
| Total Liabilities | 15K | 14K | 75K | 36K | 0 |
| Shareholder Equity | 10M | -14K | 187K | -36K | 627K |
| Total Debt | 49K | 0 | 70K | 33K | 0 |
| Net Debt | 43K | -244 | -156K | 33K | 0 |
Cash flow positioning
Latest Full Year
Operating Cash Flow
2K
+94.5% YoY
Capital Expenditures
0
Free Cash Flow
2K
+94.5% YoY
Key ratios
Gross Margin
51.2%
Operating Margin
-3927.5%
Net Margin
-3731.4%
ROE
-27.1%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.